Drugs by condition
Drugs approved for acute myeloid leukemia
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
22
Still marketed, NDA or BLA
Drug classes
9
Novel drugs
14
New molecular entities and new biologics
In development
28
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for acute myeloid leukemia.
- Filkri (Filgrastim-Laha) · Accord Biopharma Inc. Jan 15, 2026
- Komzifti (Ziftomenib) · Kura NovelBreakthrough therapyPriority reviewOrphanNov 13, 2025
- Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025
- Revuforj (Revumenib Citrate) · Syndax NovelBreakthrough therapyPriority reviewOrphanNov 15, 2024
- Nypozi (Filgrastim-Txid) · Tanvex Biopharma USA INC OrphanJun 28, 2024
All approved drugs for acute myeloid leukemia, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 2 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Leukocyte Growth Factor (6)
Nucleoside Metabolic Inhibitor (3)
Menin Inhibitor (1)
- Komzifti Ziftomenib · Kura · 2025
Hedgehog Pathway Inhibitor (1)
- Daurismo Glasdegib Maleate · Pfizer · 2018
Isocitrate Dehydrogenase 1 Inhibitor (1)
- Tibsovo Ivosidenib · Servier · 2018
Kinase Inhibitor (1)
- Rydapt Midostaurin · Novartis · 2017
BCL-2 Inhibitor (1)
- Venclexta Venetoclax · Abbvie · 2016
CD33-directed Immunoconjugate (1)
- Mylotarg Gemtuzumab Ozogamicin · Wyeth Pharms INC · 2017
Class not listed in FDA's data (7)
- Grafapex Treosulfan · Medexus · 2025
- Revuforj Revumenib Citrate · Syndax · 2024
- Vanflyta Quizartinib Dihydrochloride · Daiichi Sankyo INC · 2023
- Rezlidhia Olutasidenib · Rigel Pharms · 2022
- Xospata Gilteritinib Fumarate · Astellas · 2018
- Idhifa Enasidenib Mesylate · Bristol Myers Squibb · 2017
- Idarubicin Hydrochloride Idarubicin Hydrochloride · Pfizer · 1997
Drugs in development for acute myeloid leukemia
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- ClifutinibHEC73543Phase 32 trials
Sunshine Lake Pharma Co., Ltd. · Leukemia, Acute Myeloid (AML), Acute Myeloid Leukemia, Adult
- CrenolanibPhase 32 trials
Arog Pharmaceuticals, Inc. · Newly Diagnosed FLT3 Mutated AML, Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- GM-CSFPhase 32 trials
Y-mAbs Therapeutics · Neuroblastoma, Acute Myeloid Leukemia
- HMPL-306Phase 32 trials
Hutchmed · Acute Myeloid Leukemia, Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- XY0206Phase 31 trial
Shijiazhuang Yiling Pharmaceutical Co. Ltd · Acute Myeloid Leukemia With FLT3/ITD Mutation
- RVU120SEL120Phase 23 trials
Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- IMGN632Phase 22 trials
AbbVie · Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
- AB8939Phase 21 trial
AB Science · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
- ABD-3001DIMATEPhase 21 trial
Advanced BioDesign · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes
- ARD103Phase 21 trial
ARCE Therapeutics, Inc. · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
- BP1001Phase 21 trial
Bio-Path Holdings, Inc. · Acute Myeloid Leukemia (AML)
- CFI-400945Phase 21 trial
Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- CLN-049Phase 21 trial
Cullinan Therapeutics Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
- CTX-712Phase 21 trial
Chordia Therapeutics, Inc. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Debio 1562MPhase 21 trial
Debiopharm International SA · Acute Myeloid Leukemia
- EP0042Phase 21 trial
Ellipses Pharma · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
More on acute myeloid leukemia: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.